Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi’s 2018 Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, December 6, 2018.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Boehringer Ingelheim, Eli Lilly and Company, and Alexion Pharmaceuticals. For more information, please visit www.dicerna.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181129005144/en/
Contacts
Investor Contact:
Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com
Source: Dicerna Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20181129005144/en
